<DOC>
	<DOCNO>NCT02030847</DOCNO>
	<brief_summary>This single center , single arm , open-label phase II study determine efficacy safety single infusion autologous T cell express CD19 chimeric antigen receptor express tandem TCR 4-1BB ( TCR/4-1BB ) co-stimulatory domain ( refer CART-19 cell ) adult patient relapse refractory B-cell acute lymphoblastic leukemia . Inclusion criterion design include adult patient age great 18 B cell ALL , relapse refractory , available curative treatment option ( autologous allogeneic stem cell transplantation ) limit prognosis ( great 12 week survival expectancy ) currently available therapy . The study product CART-19 cell transduce lentiviral vector express anti-CD19 scFv TCR:41BB administer single i.v . infusion 1 5 x 108 transduced CAR T cell .</brief_summary>
	<brief_title>Study Redirected Autologous T Cells Engineered Contain Anti-CD19 Attached TCR 4-1BB Signaling Domains Patients With Chemotherapy Resistant Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Inclusion Criteria Signed inform consent form must obtain prior study procedure Relapsed refractory Bcell ALL 1 . 1st great BM relapse OR 2 . Any marrow relapse allogeneic HSCT &gt; 100 day transplant OR 3 . For patient refractory disease : . &lt; 60 year old achieve CR &gt; 2 chemotherapy regimen ii . &gt; 60 year old achieve CR 1 prior chemotherapy regimen d. Patients Ph+ ALL eligible fail tyrosine kinase inhibitor therapy Documentation CD19 tumor expression bone marrow peripheral blood flow cytometry within 3 month screen . Adequate organ function define : 1 . Creatinine &lt; 1.6 mg/dl 2 . ALT/AST &lt; 3x upper limit normal range 3 . Direct bilirubin &lt; 2.0 mg/dl 4 . Must minimum level pulmonary reserve define ≤ Grade 1 dyspnea , pulse oxygen &gt; 92 % room air , DLCO &gt; 40 % ( correct anemia clinically appropriate ) 5 . Left Ventricle Ejection Fraction ( LVEF ) ≥ 40 % confirm ECHO/MUGA Bone marrow ≥ 5 % lymphoblast Male female age ≥ 18 year A ECOG Performance Status either 0 1 No contraindication leukapheresis . Retreatment Inclusion Criteria Performance Status 01 Adequate organ system function include : Creatinine &lt; 1.6 mg/dl ALT/AST &lt; 3x upper limit normal Total Bilirubin &lt; 2.0 mg/dl Must minimum level pulmonary reserve define ≤ Grade 1 dyspnea , pulse oxygen &gt; 92 % room air , DLCO &gt; 40 % ( correct anemia clinically appropriate ) Left Ventricular Ejection Fraction ≥ 40 % No contraindication leukapheresis ( required retreatment ) Gives voluntary informed consent retreatment Exclusion Criteria Isolated extramedullary disease relapse Active hepatitis B active hepatitis C Class III/IV cardiovascular disability accord New York Heart Association Classification HIV infection Active acute chronic graftversushost disease ( GVHD ) requirement immunosuppressant medication GVHD within 4 week enrollment . Concurrent use systemic steroid chronic use immunosuppressant medication . Recent current use inhale steroid exclusionary . For additional detail regard use steroid immunosuppressant medication . Active CNS involvement malignancy . Note : Patients history CNS disease effectively treat eligible provided treatment &gt; 4 week enrollment Pregnant nursing ( lactate ) woman , female study participant reproductive potential must negative serum urine pregnancy test within 48 hour infusion Participation prior investigational study within 4 week prior enrollment longer required local regulation . Participation nontherapeutic research study allow . Patients known history prior diagnosis optic neuritis immunologic inflammatory disease affect central nervous system . Retreatment Exclusion Criteria Pregnant lactate woman . Active hepatitis B hepatitis C Concurrent use systemic steroid chronic use immunosuppressant medication . Recent current use inhale steroid exclusionary . For additional detail regard use steroid immunosuppressant medication . HIV infection Patients active CNS involvement malignancy . Patients prior CNS disease effectively treat eligible provide treatment &gt; 4 week enrollment retreatment cohort . Class III/IV cardiovascular disability accord New York Heart Association Classification Patients known history prior diagnosis optic neuritis immunologic inflammatory disease affect central nervous system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>